Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), NexImmune (NEXI) and Biomea Fusion (BMEA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viking Therapeutics (VKTX – Research Report), NexImmune (NEXI – Research Report) and Biomea Fusion (BMEA – Research Report).

Viking Therapeutics (VKTX)

Raymond James analyst Steven Seedhouse reiterated a Buy rating on Viking Therapeutics yesterday and set a price target of $35.00. The company’s shares closed last Tuesday at $15.44.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 5.8% and a 41.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, and Mirum Pharmaceuticals.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.63, which is a 100.1% upside from current levels. In a report issued on March 16, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

NexImmune (NEXI)

Raymond James analyst Timur Ivannikov maintained a Hold rating on NexImmune yesterday. The company’s shares closed last Tuesday at $0.40, close to its 52-week low of $0.19.

According to TipRanks.com, Ivannikov is ranked #8035 out of 8343 analysts.

NexImmune has an analyst consensus of Hold.

Biomea Fusion (BMEA)

According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of 8.2% and a 44.4% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Ultragenyx Pharmaceutical, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Biomea Fusion is a Strong Buy with an average price target of $39.80, which is a 73.0% upside from current levels. In a report issued on March 15, J.P. Morgan also maintained a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VKTX:

• VKTX Soars on Promising VK2735 Data
• Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
• William Blair says Viking bull thesis intact after Altimmune data
• Viking Therapeutics call volume above normal and directionally bullish
• Viking Therapeutics initiated with a Buy at Stifel